GR3036649T3 - Hormone replacement therapy - Google Patents

Hormone replacement therapy

Info

Publication number
GR3036649T3
GR3036649T3 GR20010401507T GR20010401507T GR3036649T3 GR 3036649 T3 GR3036649 T3 GR 3036649T3 GR 20010401507 T GR20010401507 T GR 20010401507T GR 20010401507 T GR20010401507 T GR 20010401507T GR 3036649 T3 GR3036649 T3 GR 3036649T3
Authority
GR
Greece
Prior art keywords
replacement therapy
hormone replacement
estrogen
antiprogestin
woman
Prior art date
Application number
GR20010401507T
Other languages
English (en)
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3036649(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of GR3036649T3 publication Critical patent/GR3036649T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
GR20010401507T 1993-02-25 2001-09-18 Hormone replacement therapy GR3036649T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy
PCT/US1994/001815 WO1994018983A1 (en) 1993-02-25 1994-02-18 Hormone replacement therapy

Publications (1)

Publication Number Publication Date
GR3036649T3 true GR3036649T3 (en) 2001-12-31

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010401507T GR3036649T3 (en) 1993-02-25 2001-09-18 Hormone replacement therapy

Country Status (25)

Country Link
US (1) US5468736A (el)
EP (1) EP0686037B1 (el)
JP (1) JP3441459B2 (el)
KR (1) KR100248857B1 (el)
AT (1) ATE202281T1 (el)
AU (1) AU680239B2 (el)
BG (1) BG62383B1 (el)
BR (1) BR9406667A (el)
CA (1) CA2157003C (el)
CZ (1) CZ290562B6 (el)
DE (1) DE69427529T2 (el)
DK (1) DK0686037T3 (el)
ES (1) ES2159552T3 (el)
FI (1) FI953926A (el)
GR (1) GR3036649T3 (el)
HU (1) HU221169B1 (el)
NO (1) NO309456B1 (el)
NZ (1) NZ262657A (el)
PL (1) PL176796B1 (el)
PT (1) PT686037E (el)
RO (1) RO115115B1 (el)
RU (1) RU2139056C1 (el)
SK (1) SK282921B6 (el)
UA (1) UA43842C2 (el)
WO (1) WO1994018983A1 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
WO2001034126A2 (en) * 1999-08-31 2001-05-17 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1390040B1 (en) * 2001-05-18 2007-01-03 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
ES2296943T3 (es) * 2001-05-23 2008-05-01 Pantarhei Bioscience B.V. Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal.
EP1390041B1 (en) * 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ATE347365T1 (de) * 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
US7923440B2 (en) * 2002-06-11 2011-04-12 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
WO2003103685A1 (en) * 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
DK1526856T3 (da) 2002-07-12 2008-03-10 Pantarhei Bioscience Bv Farmaceutisk sammensætning omfattende estetrolderivater til anvendelse i cancerterapi
ES2298570T3 (es) * 2002-10-23 2008-05-16 Pantarhei Bioscience B.V. Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
DE602004002591T9 (de) * 2003-05-22 2008-01-03 Pantarhei Bioscience B.V. Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
SI3263112T1 (sl) 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
CN101583363B (zh) * 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
MX365818B (es) 2011-11-23 2019-05-30 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016090139A1 (en) * 2014-12-03 2016-06-09 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
CA2988495C (en) 2015-06-18 2022-02-08 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
HUT72080A (en) 1996-03-28
NO309456B1 (no) 2001-02-05
CZ290562B6 (cs) 2002-08-14
PL310660A1 (en) 1995-12-27
HU9502306D0 (en) 1995-09-28
AU680239B2 (en) 1997-07-24
UA43842C2 (uk) 2002-01-15
PT686037E (pt) 2001-09-28
DE69427529T2 (de) 2001-11-22
DK0686037T3 (da) 2001-08-27
NO953243L (no) 1995-08-17
SK282921B6 (sk) 2003-01-09
ATE202281T1 (de) 2001-07-15
BG62383B1 (bg) 1999-10-29
BG99880A (bg) 1996-02-28
CZ204895A3 (en) 1996-03-13
US5468736A (en) 1995-11-21
WO1994018983A1 (en) 1994-09-01
CA2157003C (en) 2001-04-17
DE69427529D1 (de) 2001-07-26
FI953926A0 (fi) 1995-08-22
RU2139056C1 (ru) 1999-10-10
NZ262657A (en) 1997-05-26
KR100248857B1 (ko) 2000-04-01
PL176796B1 (pl) 1999-07-30
NO953243D0 (no) 1995-08-17
ES2159552T3 (es) 2001-10-16
JPH08510993A (ja) 1996-11-19
BR9406667A (pt) 1996-01-23
HU221169B1 (en) 2002-08-28
FI953926A (fi) 1995-08-22
EP0686037A4 (en) 1997-11-26
SK104995A3 (en) 1997-04-09
AU6245494A (en) 1994-09-14
CA2157003A1 (en) 1994-09-01
JP3441459B2 (ja) 2003-09-02
KR960700727A (ko) 1996-02-24
EP0686037A1 (en) 1995-12-13
EP0686037B1 (en) 2001-06-20
RO115115B1 (ro) 1999-11-30

Similar Documents

Publication Publication Date Title
HU9502306D0 (en) Hormone replacement therapy
US5460820B1 (en) Method for providing testosterone and optionally estrogen replacement therapy to women
BG101349A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
DE69710896D1 (en) Progestogen-anti-progestogen therapien
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
PT1011781E (pt) Stent com arco
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
AU1921997A (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
MY125565A (en) Intermediates and process for preparing olanzapine
TW325996B (en) Anti-atherosclerotic composition containing 17α-dihydroequilin
AU6027190A (en) Elevating table for pelvis correction
EP0642261A3 (en) Voltage regulator for supplying an electrode to a CRT.
ZA974785B (en) Growth hormone and estrogen in the treatment of osteoporosis.
AU3780897A (en) Combinations for hormone replacement therapy containing a natural oestrogen, a natural progestogen and a natural androgen
EP0671866A3 (de) Stromversorgungsschaltung für eine Entladungslampe, deren Verwendung und Verfahren zum Betrieb.
HUP9801691A3 (en) Once-a-month-injectable useful as depot contraceptive and in hormone replacement therapy for perimenopausal and premenopausal women
SU1090083A1 (ru) Электронно-гидромеханическая система регулирования подачей топлива
ES2141044A1 (es) Terapia con oxibutinina.
AU2003206424A1 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
MX9709013A (es) Forma de dosis que comprende oxibutinina.
MX9701531A (es) Terapia de combinacion para tratar la osteoporosis-polifosfonatos o progestinas y agonistas de estrogenos.
JO1813B1 (en) Slicing and forming cakes and covered with sesame
JO1748B1 (en) New polypeptide derivatives
IE883607L (en) 19-nor progesterone
AU122916S (en) An oven door panel